Compare DexCom, Inc. (DXCM) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SpaceX — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while SpaceX trades at $146.22 (market cap $1.76T). The key difference: SpaceX is far larger — about 52.1× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| DXCM | SPCX | |
|---|---|---|
Market Cap | $33.79B | $1.76T |
Sector | Health | Technology |
52-Week High | $89.53 | $202.09 |
52-Week Low | $54.84 | $108.27 |
Enterprise Value | $33.24B | $1.70T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
SPCX stock trades at $147.99, up 6.67% today, with a bullish technical signal and strong analyst support. Recent news highlights AI growth and a $1.2 billion stake by Norway's sovereign wealth fund. However, the company shows negative net income margins and high valuation ratios, with revenue growth offset by profitability challenges.
The outlook is mixed: bullish sentiment and AI expansion offer upside, but high valuation and persistent losses pose risks. The consensus price target of $228.52 suggests potential growth, yet investors must weigh innovation against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
